HIV coinfection and antiretroviral therapy enhances liver steatosis in patients with hepatitis C, but only in those infected by HCV genotype other than 3

Antiviral Therapy

Volumn 13, Issue 8, 2008, Pages 1057-1065

  Borghi, Vanni ^a   Puoti, Massimo ^b   Mussini, Cristina ^a   Bellelli, Stefania ^c   Angeletti, Claudio ^c   Sabbatini, Francesca ^a   Prati, Francesca ^a   Cossarizza, Andrea ^a   Esposito, Roberto ^a  

^a UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^b UNIVERSITY OF BRESCIA   (Italy)

^c NATIONAL INSTITUTE FOR INFECTIOUS DISEASES L SPALLANZANI   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; PROTEINASE INHIBITOR; RNA; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE;

ADULT; AGE DISTRIBUTION; ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE DURATION; DISEASE SEVERITY; DRUG EXPOSURE; DRUG RESPONSE; FATTY LIVER; FEMALE; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN TISSUE; LIVER BIOPSY; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; MIXED INFECTION; OUTCOME ASSESSMENT; PATIENT SELECTION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; VIRUS CELL INTERACTION;

ADULT; ANTI-RETROVIRAL AGENTS; FATTY LIVER; FEMALE; GENOTYPE; HEPACIVIRUS; HEPATITIS C; HIV INFECTIONS; HUMANS; LOGISTIC MODELS; MALE; ODDS RATIO; RISK FACTORS;

EID: 58149485466     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Bräu N, Salvatore M, Rios-Bedoya CF, et al. Slower fibrosis progression in HIV-1/HCV-coinfected patients with successful HIV-1 suppression using antiretroviral therapy. J Hepatol 2006; 44:47-55.
2. Braitstein P, Palepu A, Dieterich D, et al. Special considerations in the initiation and management of antiretroviral therapy in individuals coinfected with HIV and hepatitis C. AIDS 2004; 18:2221-2234.
3. Negro F. Insulin resistance and HCV. will new knowledge modify clinical management? J Hepatol 2005; 45:514-519.
4. Palella FJ, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med 1998; 338:853-860.
5. Soriano V, Puoti M, Sulkowski M, et al. Care of patients with hepatitis C and HIV-1 coinfection: updated recommendations from the HIV-1-HCV international panel. AIDS 2004; 18:1-12.
6. Rosenthal E, Poiree M, Pradier C, et al. Mortality due to hepatitis C-related liver disease in HIV-1-infected patients in France (Mortavic 2001 study). AIDS 2003; 17:1803-1809.
7. Mocroft A, Soriano V, Rockstroh J, et al. Is there evidence for an increase in the death rate from liver-related disease in patients with HIV-1? AIDS 2005; 19:2117-2125.
8. Bica I, McGovern B, Dhar R, et al. Increasing mortality due to end-stage liver disease in patients with human immunodeficiency virus infection. Clin Infect Dis 2001; 32:492-497.
9. Puoti M, Bonacini M, Spinetti A, et al. Liver fibrosis progression is related to CD4 cell depletion in patients coinfected with hepatitis C virus and human immunodeficiency virus. J Infect Dis 2001; 183:134-137.
10. Benhamou Y, Di Martino V, Bochet M, et al. Factors affecting liver fibrosis in human immunodeficiericy virus and hepatitis c virus coinfected patients: impact of protease inhibitor therapy. Hepatology 2001; 34:283-287.
11. Poles MA, Dieterich DT, Schwarz ED, et al. Liver biopsy findings in 501 patients infected with human immunodeficiency virus (HIV). J Acquir Immune Defic Syndr Hum Retrovirol 1996; 11:170-177.
12. Albisetti M, Braegger CP, Stallmach T, Willi UV, Nadal D. Hepatic steatosis: a frequent non-specific finding in HIV-infected children. Eur J Pediatr 1999; 158:971-974.
13. Zeremski M, Talal AH. Dideoxynucleoside analogues should be used cautiously in patients with hepatic steatosis. Clin Infect Dis 2006; 43:373-376.
14. Rodriguez-Torres M, Govindarajan S, Solá R, et al. Hepatic steatosis in HIV/HCV co-infected patients: correlates, efficacy and outcomes of anti-HCV therapy: a paired liver biopsy study. J Hepatol 2008; 48:756-764.
15. McGovern BH, Ditelberg JS, Taylor LE, et al. Hepatic stearosis is associated with fibrosis, nucleoside analogue use, and hepatitis C virus genotype 3 infection in HIV-seropositive patients. Clin Infect Dis 2006; 43:365-372.
16. Sulkowski MS, Mehra SH, Torbenson M, et al. Hepatic steatosis and antiretrovirai drug use among adults coinfected with HIV and hepatitis C virus. AIDS 2005; 19:585-592.
17. Monto A, Dove LM, Bostrom A, et al. Hepatic steatosis in HIV/ hepatitis C coinfection: prevalence and significance compared with hepatitis C monoinfection. Hepatology 2005; 42:310-316.
18. Marks KM, Petrovic LM, Talal AH, et al. Histological findings and clinical characteristics associated with hepatic steatosis in patients coinfected with HIV and hepatitis C virus. J Infect Dis 2005; 192:1943-1949.
19. Bani-Sadr F, Carrat E Bedossa P, et al. Hepatic steatosis in HIV-HCV coinfected patients: analysis of risk factors. AIDS 2006; 20:525-531.
20. Gaslightwala I, Bini EJ. Impact of human immunodeficiency virus infection on the prevalence and severity of steatosis in patients with chronic hepatitis C virus infection. J Hepatol 2006; 44:1026-1032.
21. Ishak K, Baptista A, Bianchi L, et al. Histological grading and staging of chronic hepatitis. J Hepatol 1995; 22:696-699.
22. Brunt EM, Janney CG, Di Bisceglie AM, Neuschwander-Tetri BA, Bacon BR. Non alcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Am J Gastroenterol 1999; 94:2467-2474.
23. Mirandola S, Realdon S, Iqbal J, et al. Liver microsomal triglyceride transfer protein is involved in hepatitis C liver steatosis. Gastroenterology 2006; 130:1661-1669.
24. Grinspoon S, Carr A. Cardiovascular risk and body-fat abnormalities in HIV-infected adults. N Engl J Med 2005; 352:48-62.
25. Macías J, Castellano V, Merchante N, et al. Effect of antiretroviral drugs on liver fibrosis in HIV-infected patients with chronic hepatitis C: harmful impact of nevirapine. AIDS 2004; 18:767-774.
26. Rubbia-Brandt L, Fabris P, Paganin S, et al. Steatosis affects chronic hepatitis C progression in a genotype specific way. Gut 2004; 53:406-412.
27. Department of Health and Human Services (US). DHHS guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents; pp. 86-87. (Updated 3 November 2008. Accessed 27 November 2008.) Available from http://aidsinfo.nih.gov/ContentFiles/GIchunks/AG_18.pdf